Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer

BACKGROUND: Limited data are available for the combination regimen of anti-programmed cell death protein 1 (PD-1) inhibitor and anti-angiogenic agents as second-line therapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC), especially in patients with squamous NSCLC. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Guanghui, Zhao, Jun, Ren, Shengxiang, Wang, Yina, Chen, Gongyan, Chen, Jianhua, Gu, Kangsheng, Guo, Renhua, Pan, Yueyin, Wang, Quanren, Li, Weixia, Yang, Xinfeng, Zhou, Caicun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096414/
https://www.ncbi.nlm.nih.gov/pubmed/35571422
http://dx.doi.org/10.21037/atm-21-4792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096414/
https://www.ncbi.nlm.nih.gov/pubmed/35571422
http://dx.doi.org/10.21037/atm-21-4792

Ejemplares similares